CRISPR technologies frequently asked questions
Can I contribute or access research tools that contain CRISPR-CAS9 technology?
Contribute: If you have developed modified cell lines using CRISPR-Cas9 please get in touch.
Access: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed below. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
ERS Genomics Ltd holds an exclusive worldwide license from Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR-Cas9 for all applications other than use as a human therapeutic. The patent rights belonging to ERS Genomics Ltd are listed below. These patent applications have broad and dominant claims covering CRISPR-Cas9 compositions and methods of genome editing in any organism.
Click to view ERS Genomics Ltd Granted Patents